Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 9

Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels

,

Panelists discuss how luspatercept’s role in ring sideroblast–negative MDS populations is evolving based on recent clinical trial data, including the COMMANDS trial and PACE-MDS study, with particular attention to the impact ofEPO levels on treatment decisions and outcomes.

Video content above is prompted by the following:

  • What is the role of luspatercept in the RS-negative population? When do you consider it as first-line treatment in this particular patient population?

Resource link: COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).

Resource link: Platzbecker U, et al. Phase II PACE-MDS study. J Clin Oncol, 2022.

Resource link: Platzbecker U, et al. Comparative biomarkers by RS status COMMANDS trial. EHA 2024, abstract P763.

  • How do EPO levels factor into your treatment approach for this patient
  • Please comment on outcomes in the COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024) based on EPO levels (<200).